Trial · NCT03395184
Adverse event totals21
The totals the trial posted for each group.
1 to 20 of 21
Download this page as JSON| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Induction Period: Placebo QD | 0 | 79 |
| Total, all-cause mortality | Induction Period: Ritlecitinib 200 mg/50 mg QD | 0 | 93 |
| Total, all-cause mortality | Induction Period: Brepocitinib 60 mg QD | 0 | 72 |
| Total, all-cause mortality | OLE Period: Placebo QD -> Ritlecitinib 50 mg QD | 0 | 36 |
| Total, all-cause mortality | OLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QD | 0 | 84 |
| Total, all-cause mortality | OLE Period: Placebo QD -> Brepocitinib 30 mg QD | 0 | 32 |
| Total, all-cause mortality | OLE Period: Brepocitinib 60 mg QD -> Brepocitinib 30 mg QD | 0 | 64 |
| Total, other adverse events | Induction Period: Placebo QD | 20 | 79 |
| Total, other adverse events | Induction Period: Ritlecitinib 200 mg/50 mg QD | 20 | 93 |
| Total, other adverse events | Induction Period: Brepocitinib 60 mg QD | 17 | 72 |
| Total, other adverse events | OLE Period: Placebo QD -> Ritlecitinib 50 mg QD | 29 | 36 |
| Total, other adverse events | OLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QD | 34 | 84 |
| Total, other adverse events | OLE Period: Placebo QD -> Brepocitinib 30 mg QD | 19 | 32 |
| Total, other adverse events | OLE Period: Brepocitinib 60 mg QD -> Brepocitinib 30 mg QD | 31 | 64 |
| Total, serious adverse events | Induction Period: Placebo QD | 6 | 79 |
| Total, serious adverse events | Induction Period: Ritlecitinib 200 mg/50 mg QD | 4 | 93 |
| Total, serious adverse events | Induction Period: Brepocitinib 60 mg QD | 4 | 72 |
| Total, serious adverse events | OLE Period: Placebo QD -> Ritlecitinib 50 mg QD | 6 | 36 |
| Total, serious adverse events | OLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QD | 10 | 84 |
| Total, serious adverse events | OLE Period: Placebo QD -> Brepocitinib 30 mg QD | 5 | 32 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03395184/event-totals